


ANNUAL GENERAL MEETING

AND TRADING UPDATE



DISCLAIMER


The material in this presentation has been prepared by Motio Ltd (“Motio”) and is general background information about Motio’s activities current as at the date of this presentation. This information is given in summary form and does not purport to be complete. Information in this presentation, including forecast financial information, should not be considered as advice or a recommendation to investors or potential investors in relation to holding, purchasing or selling securities or other financial products or instruments and does not take into account your particular investment objectives, financial situation or needs.

Before acting on any information you should consider the appropriateness of the information having regard to these matters, any relevant offer document and in particular, you should seek independent financial advice. All securities and financial product or instrument transactions involve risks, which include (among others) the risk of adverse or unanticipated market, financial or political developments and, in international transactions, currency risk.

This presentation may contain forward looking statements including statements regarding our intent, belief or current expectations with respect to Motio’s businesses and operations, market conditions, results of operation and financial condition, capital adequacy, specific provisions and risk management practices. Readers are cautioned not to place undue reliance on these forward-looking statements.

Motio does not undertake any obligation to publicly release the result of any revisions to these forward-looking statements to reflect events or circumstances after the date hereof to reflect the occurrence of unanticipated events. While due care has been used in the preparation of forecast information, actual results may vary in a materially positive or negative manner. Forecasts and hypothetical examples are subject to uncertainty and contingencies outside Motio’s control.

Past performance is not a reliable indication of future performance.



Acknowledgment of Country

artwork by Gloria Petyarre (1942-2021)

THANK YOU FOR JOINING

- 01** WELCOME TO THE MOTIO AGM
JASON BYRNE | CHAIR
- 02** AGM PROCEEDINGS
AN OVERVIEW OF THE NUMBERS
- 03** RESULTS SUMMARY & AGM TRADING UPDATE
UPDATE TO SHAREHOLDERS
- 04** SUMMARY & QUESTIONS
Q&A

ANNUAL GENERAL MEETING
September 25, 2025

NEW

CELEBREX RELIEF
celecoxib 200 mg

FOR RELIEF FROM MUSCLE & JOINT INJURIES!

Available only from your pharmacist

ASK YOUR PHARMACIST ABOUT THIS PRODUCT.
INCORRECT USE COULD BE HARMFUL.

VIATRIS

motio

01

WELCOME TO THE AGM.

JASON BYRNE | CHAIR

ersonal use only

INTRODUCTION | BOARD & MANAGEMENT



JASON BYRNE | CHAIR



HARLEY GROSSER | DIRECTOR



ADAM CADWALLADER | MD + CEO



JUSTIN KINGSTON | COO



JACQUI SMITH | FINANCIAL CONTOLLER



GORDON D'MELLO | COMMERCIAL DIRECTOR

Annual General Meeting
Motio Limited
Level 8, 140 Arthur Street
North Sydney NSW 2060
September 25, 2025

02

AGM PROCEEDINGS.

JASON BYRNE | CHAIR


03

MOTIO OVERVIEW & 10 WEEK UPDATE

ADAM CADWALLADER | CEO

HOW WE CONNECT WITH PEOPLE

- Developing fantastic networks that have high impact
- In geographies where a lot of people see our displays
- Has the precision of digital targeting
- The dynamics of video and editorial content
- Hyper relevant information
- Tailored to the natural long dwell times of each environment



ersonal use only

ersonal use only



We own and operate digital screen networks in these expanding group of environments.



RECEPTION

A digital screen in a hospital reception area displays an advertisement for Australia's COVID-19 vaccination program. The ad features a smiling female nurse in blue scrubs. To her right are four circular icons with checkmarks, each depicting a different group of people: a person in a wheelchair, a person in a stroller, a person in a walker, and a person in a wheelchair. Below the nurse, the text reads: "AUSTRALIA'S COVID-19 VACCINATION PROGRAM IS UNDERWAY." followed by smaller text: "COVID-19 vaccines will keep Australia safe and protect our way of life. The people most at risk in our communities will be vaccinated first. It's important we all continue to remain COVIDSafe. To find out when it's your turn, visit australia.gov.au or call the National coronavirus and COVID-19 vaccine helpline 1800 020 080." At the bottom, there is a "BE COVIDSAFE" logo, the "COVID-19 VACCINATION Safe. Effective. Free." logo, and the text "Authorised by the Australian Government, Canberra".

We own and operate digital screen networks in these expanding group of environments.

ersonal use only



AUSTRALIA'S MOST TRUSTED TELCO*
FOR BUSINESSES GREAT & SMALL

Aussie Broadband
Business

*As awarded by Roy Morgan

TINY'S

motio is a Placed Based Media company
that operates over 1,200 displays nationally.

ersonal use only

NEW PHARMACY ONLY MEDICINE

CELEBREX RELIEF
celecoxib 200 mg

For pain relief from muscle & joint injuries

FOR RELIEF FROM MUSCLE & JOINT INJURIES!

Available only from your pharmacist

ASK YOUR PHARMACIST ABOUT THIS PRODUCT.
INCORRECT USE COULD BE HARMFUL.

Reference: 1. CELEBREX RELIEF[®] Product Information, Millers Point, NSW. AU-CELE-3035-00036, April 2025.

VIATRIS



ersonal use only

motio is a Placed Based Media company
that operates over 1,200 displays nationally.



PCYC Commitment • Resilience • Integrity



motio

ersonal use only

POINTS BET
1ST HEAD TO HEAD BET UP TO MAX STAKE

FIRST GOAL YOU WIN

SEE ACCOUNT FOR PERSONALIZED MAX STAKE LIMIT



POINTS BET
SWANS
WIL
\$43.00 \$74.00

QR CODE



We own and operate digital screen networks in these expanding group of environments.

erson

ersonal use only



Whilst we are technology driven, our
business and culture is sales.

motio

motio is known for **transforming places** and spaces. Helping business, customers and brands gain the maximum value from digital signage.



03

FY25 RESULTS SUMMARY &
TRADING UPDATE.

ersonal use only

HIGHLIGHTS

Revenue

\$9.377M

+30%* Year On Year

CASH EBITDA

\$1.939M


291%* Increased on FY24

* Presentation of the comparative information has been restated due to a discontinued operations

YEAR ON YEAR GROWTH

Media revenue has grown

- 30% YOY Growth
- Cash flow positive
- Increased utilisation
- Sustainable business model
- Commitment to continued profitability




* Presentation of the comparative information has been restated due to a discontinued operations

AGM TRADING UPDATE

Q1FY26 revenue (proforma)

- Solid result coming into the quarter
- Revenue modestly down (\$177K) compared to pcp (excluding Spawtz)
 - Strategic decision to exit representation
 - FY25 included representation revenue (pcp was \$c. \$250K)
- Increase in GP from 75% to 80%
- Owned media sales revenue up vs. pcp
- Local sales delivering its target
- National Contract Value +35%
- Cash EBITDA forecast >\$600K for Q1FY26 (unaudited management accounts)
- Cash balance \$3m (25/9/25) with PCYC rollout already 60% funded




	Q1FY26	Q1FY25*
REVENUE	\$ 2,209,959	\$ 2,387,301
COS	\$ 441,693	\$ 596,520
GP	\$ 1,768,266	\$ 1,790,781

* Presentation of the comparative information has been restated due to a discontinued operations

FORWARD REVENUE

Current & forward media revenue comparison

- Revenue at the same time last year was 9% ahead (which included Representation revenue)
- Removing representation revenue, we are at the same point PCP
- PCYC network will take affect from Q2
- **Approximately 43% of our annual target achieved at week 12**



REVENUE TRENDS

Quarterly revenue trends


- Revenue growth profile is largely predictable
- Q1 FY26 follows yearly trending for the period
 - Q1 FY25 being the outlier
- FY26 has no representation revenue.
- Play partnership with PCYC has projected revenue growth through FY26 commencing Q2



REVENUE PER LOCATION

Annualised revenue per location

- Yield continues to increase
- Exceeded the \$9K RPL in Q1 (annualised)
- Monetising inventory more efficiently
- With combination of volume and yield
- Representation sites drop off from Q2 FY25, and in totality at Q1 FY26



04

SUMMARY & QUESTIONS.

SUMMARY.

- Solid start to FY26 with higher Revenue per location
- Costs down & margin increase = flow through bottom line
- PCYC Roll out will be completed in 2 weeks which will provide growth
- Opportunity to roll out into a significant number of new Health sites funded internally without need for external funding
- Cash flow and cash balances healthy
- Quality team in place
- Forward momentum established across the business
- Continued focus on bottom line profitability and a sustainable business model



ersonal use only

QUESTIONS